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Tailoring Therapeutic Responses via Engineering
Microenvironments with a Novel Synthetic Fluid Gel
Nicola C. Foster, Piers Allen, Alicia J. El Haj, Liam M. Grover, and Richard J. A. Moakes*
This study reports the first fully synthetic fluid gel (SyMGels) using a simple
poly(ethylene glycol) polymer. Fluid gels are an interesting class of materials:
structured during gelation via shear-confinement to form microparticulate
suspensions, through a bottom-up approach. Structuring in this way, when
compared to first forming a gel and subsequently breaking it down, results in
the formation of a particulate dispersion with particles “grown” in the shear
flow. Resultantly, systems form a complex microstructure, where gelled
particles concentrate remaining non-gelled polymer within the continuous
phase, creating an amorphous-like interstitial phase. As such, these materials
demonstrate mechanical characteristics typical of colloidal glasses,
presenting solid-like behaviors at rest with defined yielding; likely through
intrinsic particle-particle and particle-polymer interactions. To date, fluid gels
have been fabricated using polysaccharides with relatively complex
chemistries, making further modifications challenging. SyMGels are easily
functionalised, using simple click-chemistry. This chemical flexibility, allows
the creation of microenvironments with discrete biological decoration.
Cellular control is demonstrated using MSC (mesenchymal stem
cells)/chondrocytes and enables the regulation of key biomarkers such as
aggrecan and SOX9. These potential therapeutic platforms demonstrate an
important advancement in the biomaterial field, underpinning the
mechanisms which drive their mechanical properties, and providing a
versatile delivery system for advanced therapeutics.
1. Introduction
The role of biomaterials within medicine and tissue engineer-
ing has received growing attention within recent years, although
their usage has been documented for millennia.[1] Scientific and
technological advances have led to vast improvements within
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healthcare, stimulating the next gen-
eration of increasingly more complex
materials.[2,3] One such leap was demon-
strated in the 1930s, where advances in
synthetic polymers led to applications
ranging throughout the human anatomy:
cardiovascular, orthopaedics, ophthalmic,
dental and neural.[4] These polymeric scaf-
folds provided replacement of the “inert”
standards of care, with no inherent regen-
erative properties, with those capable of,
for example, stimulating osteoconductive
mechanisms.[5] The principle of providing
scaffolds for cell infiltration and native heal-
ing processes is not limited to bone. Many
soft tissue applications have been addressed
through the use of synthetic scaffolds, how-
ever, the complex nature of many diseases
still demand better integration and/or func-
tionality combined with suitable delivery
approaches. Decellularized tissue scaffolds
have been proposed to address structural
and biological cues, as the extracellular
matrix (ECM) provides a direct mimetic
of the native environment.[6,7] Although
theoretically ideal and currently used in
the clinic for multiple applications, the re-
quirement for harsh chemical processing,
potential variation between batches and patient rejection,[8] have
hindered large scale adoption. Hydrogels have been regarded as
an alternative for such materials, providing an ECM-like struc-
ture to immobilise cells for transplantation.[9] Their tolerance
in biological environments, high-water content, mass transport
and versatility have directly resulted in such materials becom-
ing adopted into numerous tissue engineering and drug delivery
applications.[10] However, translation of these new materials is
still slow, with large costs surrounding toxicology studies stem-
ming from chemical, physical and morphological roles in modu-
lating cellular events.[11]
One means of navigating the high costs and risks posed by the
translation processes is through the use of currently approved
materials, and re-structuring them through a microstructural
design process.[12] Commonly used throughout many industries,
the microstructural design approach to formulation engineering
focuses on the interplay between three key areas: raw materials,
processing and material properties.[13] Again, hydrogels have
lent themselves to such approaches,[14,15] where careful control
over chemical properties such as polymer concentration, chain
length, chemical backbone (hydrophobic/hydrophilic balance),
charge and branching,[16] and processing parameters, degree
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of curing/gelation,[17] allow for the manipulation of material
behaviors including strength, elasticity and yielding. This tech-
nique can be employed to materials commonly found within
the medical field (PGLA, PEG, alginate, etc.) using processing
strategies (mixing, drying, heating, etc.), or specific chemistries
(phase separation, pH, electro-potential), to fabricate materials
with increasingly complex mechanical behaviors.[18] Indeed,
granular hydrogels, where the formation of microgel particles
can be facilitated through either templating (phase separation
techniques such as emulsions and microfluidic devices) or shear
break down of a pre-formed gels, are key examples of using
processing to influence bulk mechanical properties.[19,20]
Fluid gels, again microgel suspensions, use a bottom-up ap-
proach to controlling particle formation; “grown” through a nu-
cleation and growth mechanism, which is ultimately controlled
by shear imparted on the system.[21] Gelation kinetics therefore
play a pivotal role during the fabrication process, with resulting
suspensions determined by the equilibrium between gel growth
(gelation kinetics) and extent of mixing (timescale of shearing,
shear rate).[22] By controlling microgel formation in this way, it is
possible to engineering rheological properties, arising through
weak interactions at the particle interfaces, where complete gela-
tion has not been allowed to occur.[23–26] Ultimately, these densely
packed gelled particles have the ability to “squeeze” past each
other under large strains, providing a pseudo-solid behavior at
rest with prominent shear thinning capacities.[26–28] Apart from
their rheological characteristics, their one-step manufacturing
process and compatibility with regulator-approved materials, has
likely driven their application within the translational field, pro-
viding a highly dynamic platform for a range of therapies: lead-
ing to enhanced retention and delivery in ocular applications;[29]
keratinocyte delivery for burn wounds;[30] and, determination of
cell fate through controlled geometric constraint.[31] Although
the versatility of such materials has been demonstrated, they
are still limited within highly complex healing pathways for ex-
ample, angiogenesis, where multi-stage mechanisms require de-
livery of specific actives at different timescales.[32] A proposed
method of obtaining such defined release profiles are through
programmed delivery techniques, whereby chemically sensitive
bonding is used to retain therapeutics on the gel, releasing once
stimulated by a biological cue.[33] Although functionalization of
polysaccharide-based materials is achievable,[34–36] chemical al-
teration is typically undertaken prior to gelation, accompanied
by complicated synthesis and at risk to affecting gelation prop-
erties thereafter.[37] As such, the often-complex chemical struc-
tures (in terms of both chemical moieties and disparity in re-
peating saccharide units) of the polysaccharides currently used
to formulate fluid gels, do not lend themselves to easily facilitate
chemical tethers between microgel particle and biologically ac-
tive molecules. Thus, to date, fluid gels have not enabled highly
modulated therapeutic delivery systems, instead relying heavily
on diffusion mechanisms to mediate payload release.
This study, reports a fluid gel formed using with a synthetic
polymer, poly(ethylene glycol); due to its clinical relevance, be-
ing commonly used in CE marked medical devices. In this way
the resultant materials are open to further functionalization,
through the addition of pendant groups, small molecules or pro-
teins, which can be used to direct cell response. As such, PEG-
based fluid gels (SyMGels – microgel suspensions specifically
fabricated through a bottom-up approach), were prepared and
characterised for their mechanical characteristics. Cell behav-
iors were evaluated in 2D culture, pre- and post-functionalization
with a range of biologically relevant macro-molecules, in order to
demonstrate the capabilities for control over the cellular microen-
vironment. Moreover, functionalized-SyMGel’s potential to drive
healing was investigated in vitro, specifically focused on field of
cartilage therapy: aiming to enhance current clinical practises
in cell therapy,[38] through effective delivery/creation of a pro-
healing environments, to help improve and ensure engraftment.
2. Results
2.1. Fabrication of Microgel Suspensions
Synthetic microgel suspensions (SyMGels) were prepared us-
ing a shear-gel technique previously reported for polysaccharide
based fluid gels;[12,21,31,39,40] whereby shear was applied to a poly-
mer sol undergoing a sol-gel transition. This process has been
depicted in Figure 1a, highlighting the use of UV light to stim-
ulate the formation of radicals (Figure 1ai) which promote free
radical polymerisation, propagating through the carbonyl species
within the acrylate groups (Figure 1aii). However, unlike typi-
cal polymerisation processes, growth termination is controlled
by the presence of shear, resulting in a particulate suspension
instead of a single continuous network (Figure 1aiii).
Building on previously reported data showing a direct corre-
lation between particle formation and viscosity increase,[21,28,41]
the reduction in vortex (liquid height), as result of thickening,
was used as a qualitative means to measure gelation (Figure 1b).
It was observed that all systems, irrespective of the mixing ap-
plied, started to gel (defined as the onset of change) after the same
length of irradiation, ca. 65 s, undergoing a decrease in vortex
height until a secondary plateau/equilibrium was reached. Com-
parison of the profiles highlighted a shift in the “rate of gelation”,
with higher mixing speeds resulting in slower curing.
The extent of gelation was further probed using centrifuga-
tion to separate the gelled and continuous phases (Figure 1c). In-
creasing the shear applied during processing resulted in a linear
increase (p < 0.01) in extractable continuous phase, highlight-
ing a reduction in the degree of gelled particles being formed
throughout curing. The effect of mixing on both particle size and
morphology has been shown in Figure 2. A static light scatter-
ing technique was used to determine size distributions for all
SyMGel systems (Figure 2ai). In all cases, SyMGels showed a
broad monomodal peak, suggesting a range of particle sizes. Av-
erage particle size, D[4,3] values, were determined to show av-
erage changes in particle size (Figure 2aii). Again, a linear rela-
tionship between the applied mixing and resultant particle size
was clearly observed, forming larger particles at low mixing rates
(308±28 µm at 300 rpm) and smaller particles at higher process-
ing rates (24±0.8 µm at 700 rpm). Particle micrographs cohere
with sizing data, showing a reduction in size as a function of the
mixing applied (Figure 2b). Particle morphology appeared to in-
crease in uniformity as the mixing was increased, characterised
by a higher length to width ratio. More in-depth analysis of the
particle structure, using confocal microscopy, highlighted a rela-
tively thin structure to the particles, represented by a “disc-like”
shape ca. 10 µm in thickness (Figure 2c).
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Figure 1. Formation of synthetic microgel suspensions (SyMGels) via sheared gelation. a) Schematic representation for the fabrication of SyMGels,
with proposed gelation mechanism: i) radical formation; ii) initiation and propagation, and; iii) restriction of gel growth through applied shear to form
terminated particles. b) “Gelation” profiles for SyMGels prepared at mixing rate of either 300 or 700 rpm. Profiles were obtained by measuring the
deviation from initial liquid height as a function of time as shown by the photographic representations at 0, 75, and 120 s (700 rpm). c) Determination of
the gelled phase using centrifugation. Mass of continuous phase removed as a function of processing mixing rate from a 0.5 g aliquot after centrifugation
at 17000 rcf for 10 min. All data presented is the average on n = 3, with error bars demonstrating the 95% confidence interval. Statistical analysis was
conducted using one-way ANOVA with significance denoted as * p < 0.05, ** p < 0.01, and *** p < 0.001.
2.2. Suspension Material Properties
SyMGel viscoelasticity was studied under both small (Figure 3)
and large deformation (Figure 4). Linear rheology was used to un-
derstand SyMGel behavior at rest. At 1 Hz, all SyMGel systems
were characterised by a storage modulus (G′) that dominated the
loss modulus (G″). Increasing the stress applied to the systems
resulted in a shift out of an equilibrated state (LVeR), to the extent
that a cross-over to a loss dominated system (G″ > G′) occurred
(Figure 3a). Mechanical spectra for the storage moduli, under in-
creasing stress were collapsed to show superimposablity, with all
curves displaying the same LVeR and reduction in G′ thereafter
(Figure 3d). Frequency dependent data obtained at a stress within
the LVeR for all systems highlighted that SyMGels prepared at
the highest mixing rate, 700 rpm, behaved as a viscoelastic liq-
uid initially dominated by the loss modulus and crossing-over at
higher frequencies to G′ dominance. However, for all other sys-
tems, across the full frequency range studied (0.01–10 Hz), G′
dominated G″, suggesting gel-like behaviors. Gel strength was
characterised by both magnitude of G′ and loss tangent (tan𝛿).
All systems showed weak gel-like behaviors exhibiting values for
tan𝛿 ranging between 0.2 and 0.9 (Figure 3e), with spectra show-
ing varying frequency dependencies. Frequency dependence was
quantified by applying a fit to the data and comparing the power
indices (Figure 3c), showing less of a dependency, 0.14, for sys-
tems prepared at 300 rpm increasing to 0.15, 0.29, 0.46, and 0.66
for systems prepared at 400, 500, 600, and 700 rpm, respectively.
Non-linear rheology was used to better understand the materi-
als ability to flow at large strains (for example, if injected). All sys-
tems showed highly shear thinning suspensions which could be
closely fitted to the Cross model (Figure 4a), providing a means of
comparing between systems. Data obtained from fits to the Cross
model have been presented in the table in Figure 4d, showing
similar values for the critical shear rate required to induce flow
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Figure 2. Synthetic microgel particle shape and size. a) static light scattering data for SyMGels prepared at various mixing rates. i) Particle size distribu-
tions as a function of processing mixing rate and ii) volume weighted averages (D[4,3]) taken from the distributions showing a decreasing linear trend
in size as a function of applied mixing. b) Optical micrographs obtained using phase contrast microscopy for diluted (1:4) SyMGel systems prepared
at varying mixing rates. c) 3D stacked CSLM images rotated through 90° and 180° to show particle thickness (particles prepared at 300 rpm). Gelled
particles were stained with Rhodamine 6G and images using a 543 nm laser. (Scale bars represent 100 µm). All data presented is the average on n = 3,
with error bars demonstrating the 95% confidence interval.
(1/C) and thinning index (m) for all systems; correlating closely to
the amplitude data presented in Figure 3d. Changes in zero shear
viscosity (𝜂0) were plotted as a function of processing rate (Fig-
ure 4b) and particle volume fraction (𝜑gel) (Figure 4c), in order to
understand the extent that material viscosity was dependent on
processing.
𝜂0 correlated closely with data collected for gel strength, de-
creasing from 14.02±8.9 Pa s at 300 rpm to 0.6±0.2 Pa s at
700rpm, suggesting the resulting volume occupied by the par-
ticles plays a key role in system rheology. Data collected for the
degree of gelation (Figure 1c) was therefore used to determine
particle volume factions (𝜑gel), assuming the density of the su-
pernatant removed to be that of PBS (1.065 g cm−3). In order to
probe material behavior further, 𝜂0 was fitted to a model proposed
for concentrated flexible linear polymers solutions (Equation 1),
substituting the term for polymer length with the volume occu-
pied by the gelled particles, 𝜑gel
𝜂0 = KT M3.4 (1)
where KT was used as a fitting factor and M has been replaced by
the particle volume fraction, 𝜑gel. Correlation to the model sug-
gests that SyMGels behave similarly to concentrated polymer so-
lutions, where decreasing the mixing rate throughout processing
results in a more “highly concentrated” solution; with particles
likely providing an excluded volume effect.
2.3. Functionalization of SyMGels to Control Cellular
Microenvironments
Functionalization of the particles with various bio-
macromolecules was achieved via a Michael-type reaction
between the thiol groups (present within the cysteine residues
of the proteins, fibronectin and Wnt-3a, and grafted onto
hyaluronic acid) and the unreacted carbonyl groups on the
particle surface;[42] found at the polymer terminating ends and
gel junction zones (Figure 5a). Bonding of the protein to the
particle surface was determined using immunohistochemical
and fluorescent protein binding. Micrographs showed localisa-
tion of both the fibronectin and hyaluronic acid to the surface of
the particle (Figure 5b), however, coverage was not homogenous
across all particles, with some particles remaining un-coated
across all systems. Moreover, when functionalized with the
fibronectin, cells were seen to attach to the particle interface
(Figure 5c), resulting in morphological changes towards a more
spheroidal nature. Again, cell adhesion was not observed across
all particles.
The ability to manipulate cellular microenvironments,
through specific decoration of the SyMGel particles was studied
using both reporter cells and quantitative polymerase chain re-
action (qPCR). Wnt-3a activation of cells was determined using
a luciferase assay (Figure 5d). In the presence on the SyMGels
only, no change in cell activation, as determined by fluorescence
intensity, was observed; confirmed by fluorescent microscopy.
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Figure 3. Mechanical behavior of SyMGel systems. a) Amplitude sweep, stress controlled, for SyMGel suspensions prepared at either 300 or 700 rpm. b)
Frequency sweeps obtained at 0.04 Pa stress for SyMGels prepared at 300 and 700 rpm. c) Storage moduli (G′) obtained via frequency sweeps (0.04 Pa
stress), as a function of processing mixing rate. Lines of best fit added to each data set with equation of the line shown in the legend. d) Collapsed
amplitude sweeps for SyMGels prepared at varying processing mixing rates. e) Change in Tan𝛿 as a function of the processing mixing rate used during
SyMGel curing. All data presented is the average on n = 3, with error bars demonstrating the 95% confidence interval.
However, once functionalized (Wnt-SyMGel), a statistically sig-
nificant (p = 0.001) increase in fluorescence was demonstrated,
signifying both attachment of the protein, and more importantly
retained activity. Fibronectin- (FN-SyMGel) and hyaluronic acid-
(HA-SyMGel) functionalized systems demonstrated the ability
to regulate both aggrecan (ACAN) and SOX9 expression, respec-
tively (Figure 5e). Here, expression was shown to be dependent
on both the decoration of the particles and the culture medium.
Non-functionalized SyMGels, irrespective of media type (basic
or chondrogenic), demonstrated no change in either the ACAN
or SOX9 gene. However, once functionalized, FN-SyMGels (Fig-
ure 5ei), showed the ability to both upregulate ACAN (300 rpm
samples, p < 0.05) in the presence of basic media; or, down
regulate the same gene (500 rpm samples, p < 0.001) when
cultured in chondrogenic media. HA-SyMGels (Figure 5eii)
showed similar results for the expression of SOX9, showing a
significant (p < 0.01) increase in the presence of chondrogenic
media.
3. Discussion
Over recent years the need for new materials which can aid regen-
erative medicine processes has become increasingly more appar-
ent. One class of materials which, due to their unique material be-
haviors, have gained much attention are fluid gels. Fluid gels, like
their quiescently gelled counterparts, possess all of the widely-
reported advantages of hydrogels (high water-holding capacities,
biocompatibility, ECM-like structures, good mass transport), yet
they also offer the ability to control the microstructure through-
out the gelation process into a particulate suspension, which re-
sults in solid-like behavior at rest and liquid-like behavior on
shearing.[25] This has provided a dynamic platform, that can be
easily applied as a liquid, rapidly re-structuring in situ, forming
a solid-like material with high retention properties. Thus, such
systems can be employed across a wide variety of applications
unsuited to more conventional hydrogels including: therapeu-
tic ocular delivery, cell spraying and 3D printing.[12,29–31,40,43] To
date, these materials have only been demonstrated using polysac-
charides as the gelling polymer, which despite offering numer-
ous advantages compared to synthetic polymers, are chemically
limited with regard to the addition of functional groups/co-
polymerisation (both previously shown to provide versatile deliv-
ery and breakdown mechanisms).[1,44–47]
This study demonstrated the first fabrication of synthetic
polymer fluid gels, using photo-polymerisation to undertake
gelation; resulting in a suspension of discrete gelled particles,
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Figure 4. Flow behavior of the SyMGel suspensions. a) Shear rate ramps for SyMGels prepared at mixing rates of 300 and 700 rpm obtained over a
1 min sweep. Fit to the Cross model applied and used to determine data presented in the table below it. b) Zero shear viscosity (𝜂0) data obtained using
the Cross fit plotted as a function of processing rate. c) Zero shear viscosity plotted as a function of the particle volume fraction (𝜑gel) determined using
the centrifugation data presented in Figure 1c. Fit to Mark-Houwink equation for concentrated systems (M > Mc), 𝜂0 = KT M3.4, where KT was used as a
fitting factor and M has been replaced by the particle volume fraction, 𝜑gel. d) Table of data collated from fitting flow profiles to the Cross model where,
𝜂0 is the zero-shear viscosity, 𝜂∞ is the infinite shear viscosity, 1/C is the critical shear value to induce thinning, m is the thinning index, and R
2 is the
statistical measure of fitting. All data presented is the average on n = 3, with error bars demonstrating the 95% confidence interval.
henceforth termed SyMGels (Synthetic MicroGel suspensions).
The formation of these gels followed a typical free radical poly-
merisation process, whereby junction zones were formed via
radical-induced bonds between the acrylate groups at the end of
the PEGDA chains.[48] Increases in polymer chain length during
propagation resulted in polymer precipitation, phase separation
and the formation of water-in-water gelled nuclei.[49] Interfacial
polymerisation from the surrounding polymer provides growth
of the nucleated regions, undergoing the Trommsdorff-Norrish
effect, and finally the formation of anisotropic particles. Changes
in viscosity accompanying auto-acceleration, as the gelled entities
changed the effective phase volume of the system (trapping of
the continuous phase),[50,51] coupled with gel shrinkage[52] were
used as the basis to qualitatively assess and compare the gelation
process; by measuring changes in sol volume throughout pro-
cessing. Data collected suggested the ability to control the kinet-
ics of suspension formation. Although there was little change in
the lag time prior to gelation, increased mixing slowed the curing
process, augmenting the time required to reach an equilibrium
between both gelling and shearing processes. Ultimately, termi-
nation was hindered by two factors, the increase in system vis-
cosity and the applied mixing. As such, particle formation could
take two routes: 1) formation of particles in the shear flow, or, 2)
rapid formation of gel particles and subsequent break down.[22,53]
However, in both cases size is dictated by the shear/turbulent
flow of the processing unit,[21] with particle morphology subse-
quent to the energetically more favourable gelation in line with
shear-flow.[28] It is therefore understandable that increased mix-
ing (shear separation) during gelation resulted in a lower degree
of particle formation, increasing residual non-gelled polymer.
The interplay between material behavior and microstructure
has long been established with many materials shown to be
a function of intrinsic properties such as particle size, shape,
crosslink density, etc. SyMGels demonstrated highly tuneable
rheological properties as a function of a single processing param-
eter, mixing speed. Dynamic stress sweeps identified three key
regions: linear region (𝜎 > 𝜎c); the onset of visco-plastic yield-
ing (sc < sy < sf); and, complete fluidisation (s > sf). Interestingly,
although the magnitude of the storage modulus (G′) changed de-
pending of the degree of mixing applied during fabrication, once
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Figure 5. Controlling cellular microenvironments through functionalization. a) Schematic showing the proposed mechanism for the functionalization of
SyMGel particles with bioactive molecules and ECM components. Mechanism is based on a typical Michael-type reaction, reactions steps from reactants
to product are highlighted in (i) through to (iii). b) Optical micrographs with fluorescent overlays of SyMGel particles (prepared at 300 rpm) functionalized
with fibronectin (FN) and hyaluronic acid (HA). (Scale bar represents 100 µm). c) Micrograph of a FN-SyMGel particle (prepared at 300 rpm) with
chondrocytes adhered to the surface. (Scale bars represent 100 µm). d) Wnt-SyMGel activation using a luciferase reporter line. Micrographs visually
shows activation of the cells via fluorescence. (scale bar represents 150 µm). e) Control over key chondrocytic markers using, i) FN-SyMGel and ii) HA-
SyMGel (300 rpm) microenvironments. All data presented is the average on n = 3, with error bars demonstrating the 95% confidence interval. Statistical
analysis was conducted using two-way ANOVA with significance denoted as * p < 0.05, ** p < 0.01 and *** p < 0.001.
collapsed, all plots were identical, suggesting a similar mecha-
nism for suspension stability and breakdown. Such inferences
were reiterated in the large deformation data, with flow profiles
fitted to the Cross model, highlighting similarities across critical
flow values (1/C) and thinning indices (m). Comparison of the
zero shear viscosity (𝜂0) as a function of the particle volume frac-
tion (𝜑gel) provided a fit to the Mark-Houwink equation for con-
centrated flexible linear polymer chains.[54] It is suggested such
behaviors arise from the unreacted polymer at the particle surface
and non-gelled PEGDA, forming a secondary non-gelled inter-
stitial phase; this phase then becomes increasingly concentrated
with 𝜑gel as the particles effectively trap the continuous aqueous
phase (Figure 6). To this end systems are analogous to a semi-
crystalline matrix surrounded by amorphous polymer, similar
to systems described for soft-particle and colloidal glasses.[55–59]
As such, SyMGel small deformation rheology can be described
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Figure 6. Complex fluid gel microstructure. Schematic diagrams of the complex fluid gel microstructure showing i) the system at the macroscale (inserts
used to better depict the amorphous-like interstitial phase and particle structures). ii) Diagram showing the various system interactions: * polymer-
polymer entanglements in the interstitial phase; ** particle-particle interactions when in close proximity; *** particle-polymer interactions formed at the
particle interface and interstitial layers.
in the same way,[58] behaving as a solid at low stresses/strains,
whilst shear thinning in their non-linear regimes exhibiting
liquid-like behavior.[55,60] As 𝜑gel increases the system becomes
increasingly confined, resulting in systems where Brownian mo-
tion is no longer possible, leading to dynamic arrest, as parti-
cles form “cages” that sterically prevent movement,[55,56] until a
jammed system is reached (typically at 𝜑 ca. 0.83).[61] Such obser-
vations are mirrored in the oscillatory data, with particles formed
at lower processing rates (>𝜑gel) demonstrating less frequency
dependency, as polymer relaxation kinetics increase, from result-
ing confinement.[56,59]
These key rheological, soft-particle glass properties are what
drive the material to be so versatile within regenerative medicine.
The sliding nature of particle-past-particle at large strains not
only prevents the formation of debris-based impurities associated
with quiescent gel break-up, but also largely provides the high re-
tention times associated with such materials. It is proposed that
under dynamic oscillatory movement, typically associated with
articulated regions of the body, yielding in soft-glasses occurs as
particles begin to “squeeze” past each other.[62] However, as par-
ticles are able to interact within a cage-like surrounding (a single
particle surrounded by immediate neighbours), complete frac-
turing is prevented, forming a continuous flowing network.[62]
It is likely that these interactions and caging are what prevent
expulsion between surfaces during manipulation, resulting in
an “elastic-like” fluid. To this end, the complex microstructure
formed as a consequence to the bottom-up approach accounts
for the ability to provide structure at relatively low particle vol-
ume fractions, not always obtainable from top-down or templat-
ing techniques.[24,63–67] Such systems, where solid-like behaviors
are not dependent on forming a “jammed” system hold a poten-
tial for improved integration, as a more open structure is less im-
peding to biological entities. Therefore, such matrices provide the
perfect environment to offer extended therapeutic delivery under
dynamic conditions.
Bespoke cellular microenvironments were fabricated through
the functionalization of SyMGel particles using exemplar
bio-macromolecules relevant to cartilage tissue engineering:
providing a mechanism to deliver previously rapidly cleared (low
viscosity) therapies, to dynamic anatomic areas. A Michael-type
reaction was used to covalently decorate the particles, taking
advantage of the unreacted acrylate groups that consequently
remained due to the shear processing.[21,42] The simple nature of
such click-chemistry provided numerous advantages including
compatibility with sensitive biological entities, removal of harsh
chemicals and simplified processes, all of which greatly en-
hance the potential of translation towards clinic. Unfortunately,
disparity between particle coating was observed: possibly due
to the high surface area of a particulate system; poor mixing
throughout the functionalization step, with glassy “caging”
preventing long range diffusion; and/or variation in particle
surface properties, as polymer termination differs dependent on
the potential mechanism of formation. The latter explanation
seems to hold true for SyMGels prepared at higher processing
rates, where no fibronectin attachment could be observed using
immunohistochemical imaging.
Cellular microenvironments are critical to biological processes
throughout the human body, with cell response and fate often
governed by the intrinsic chemical, mechanical and biological
cues provided by their surrounding substrates.[68–71] The ability
to mimic such stimuli provides the regenerative medicine tool-
box with a means to active both exogenous (if being implanted)
and endogenous cells, in a way that promotes improved and inte-
grated healing, by triggering native cellular pathways. Once func-
tionalized, SyMGels highlighted such a capacity, demonstrating
a propensity to drive cellular function. Chondrocytes provided
a prime example to demonstrate this, as loss of their native
environment quickly effects their downstream signalling:[72,73]
ultimately driving the production of fibrocartilage (inferior tissue
matrix) instead of the clinically relevant hyaline cartilage found
within articulated regions of the joint. To this end, FN-SyMGels
were able to maintain cell phenotype, preventing the regression
from spheroidal (typical of native chondrocytes) to spindle-like
morphology, often a consequence to 2D culture.[74,75] Moreover, a
high level of control over gene expression was achieved through
the interplay between decoration of the gelled particles and
simulating the release of cytokines (addition of chondrogenic
media); demonstrating the ability to either up/down regulate
signalling pertinent to proteoglycan formation, and essential to
the proper load-bearing function of articular cartilage.[76,77] This
result was not isolated to fibronectin, where other molecules
including hyaluronic acid and Wnt-3A, also demonstrated the
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ability to switch on specific signalling pathways; again, all directly
associated with the formation of hyaline cartilage.[78–83] Indeed,
previous reports have shown that attachment of Wnt-3A to
surfaces can influence asymmetric division and proliferation of
stem cells.[84,85] This work demonstrated similar properties, sug-
gesting that such processes can be maintained using our SyMGel
approach, aligning better with injectable cell therapeutic deliv-
eries. It is believed that chemically binding the bio-molecules to
the particle interface presents a way of locally targeting the cells,
whilst maintaining mechanical support. It is therefore suggested,
that as the exemplar molecules used in this study did not lose
their characteristic functions, functionalising is not restricted
to osteo-chondral applications, but could be used as a platform
technology.
Ultimately, the simple chemical framework of the SyMGels
facilitated an ease of functionalization, previously not achiev-
able with the complex sugar chains used to fabricate current
fluid gels. As such, these materials have the potential to be im-
planted in a minimally invasive way, to highly challenging ar-
eas of the body; for example, dynamic regions such as articu-
lated joints, where large strains can result in either breakdown
of solid (hydrogel) structures, or rapid clearance of liquid ther-
apies. Therefore, SyMGels could provide a highly versatile plat-
form in advanced therapies, where careful control over the dec-
orating molecule, provides the ability to drive proper healing
processes.
4. Conclusion
This study demonstrates the first report of fluid gels fabri-
cated using synthetic precursors (SyMGels). The formation of
such materials followed a semi-typical photo-radical polymerisa-
tion process, however, instead of becoming terminated by “cap-
ping”, growth of the gelled particles is controllable by the shear-
processing. Characterization of these systems has, for the first
time, been able to demonstrate the complex microstructure of
fluid gels; analogous to semi-crystalline systems with gelled par-
ticles suspended between free, amorphous-like, polymer within
the continuous medium. Such structuring drives the mechani-
cal properties, leading to behaviors akin to soft colloidal/particle
glasses, with rheology highly dependent on the processing upon
fabrication. Ultimately, mechanical behaviors were governed by
the phase volume occupied by the particles, where gelation at
higher shear resulted in less dense packing, and thus a higher
degree of freedom within cages formed by neighbouring par-
ticles. Cytocompatibility was also observed to be a function of
the processing, again, where more non-gelled polymer remained,
cell viability was lower. Particle functionalization with exemplar
bio-molecules, fibronectin/Hyaluronic acid/Wnt-3A, led to en-
hanced cell responses, demonstrating signs of adherence, and
importantly, being able to control signalling pathways conducive
to healing. As such, these systems present a versatile material
with the capacity to create cellular microenvironments with both
mechanical support and biological cues. Ultimately, systems have
the capacity to be retained in highly manipulated regions of the
body, offering the potential to deliver therapeutics or provide a
dynamic scaffold for cell infiltration, and facilitate native tissue
repair.
5. Experimental Section
Materials: Poly(ethylene glycol) diacrylate (Mn 700) (Sigma Aldrich),
phosphate buffered saline (Sigma Aldrich), fibronectin (Sigma Aldrich),
recombinant mouse Wnt-3a protein (R&D Systems), HyStem thio-
lated hyaluronic acid (Sigma Aldrich), 1-[4-(2-Hydroxyethoxy)-phenyl]-
2-hydroxy-2-methyl-1-propane-1-one (Irgacure 2959) (Sigma Aldrich),
2-hydroxy-2-methyl-1-phenylpropanone (Omnirad 1173) (IMG Resins),
Rhodamine 6G, 1% bovine serum albumin (BSA) (Cell Signalling Technol-
ogy), anti-fibronectin anti-body (Abcam 32419), Goat Anti-Rabbit antibody
FITC (Bertin Pharma), PrestoBlue (Invitrogen), NucBlue (Invitrogen), TRI
Reagent (Sigma Aldrich), High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems), SYBR Green PCR Mastermix (Applied Biosystems),
QuaniTect Primer Assays for human GAPDH1 and SOX9 (Qiagen).
Fabrication of Synthetic Microgel Suspensions (SyMGels): Synthetic
microgel suspensions (SyMGels) were prepared by first diluting
poly(ethylene glycol) diacrylate (Mn 700) (PEGDA) in phosphate buffered
saline (PBS), resulting in a 3% (v/v) solution. After transferring to a cell
stirrer flask, the solution was mixed and UV initiator, 2-hydroxy-2-methyl-
1-phenylpropanone (Omnirad 1173), added at a final concentration of
0.1% (v/v) and allowed to mix for 30 s. Once mixed, stirring was set
to either 300, 400, 500, 600, or 700 rpm. An OmniCure s2000 (Lumen
Dynamics Group Inc., Canada) fitted with 5 mm light guide and standard
filter (320–500 nm) was placed in the top of the stirrer flask and used
to irradiate the mixture for 4 min. A Veho USB microscope was used to
record changes in liquid height throughout the curing process. Following
irradiation, mixing was continued for a further 30 s to prevent any residual
curing in the absence of shear. Samples were then stored at 4 °C until
further use.
Functionalized SyMGels (FN-SyMGels) were prepared by first prepar-
ing the gel as described above, and subsequently mixing with an excess of
fibronectin (100 µg mL−1), Wnt-3a (400 ng mL−1), or thiolated hyaluronic
acid (100 µg mL−1) at pH 8. Systems were then warmed at 40 °C for 1 h
in a water bath allowing the additive and gel to react, before washing (via
centrifugation) with PBS and stored at 4 °C until further use.
Video Analysis of the Curing Process: Material changes throughout cur-
ing were ascertained using video analysis in MATLAB (MathWorks). In
brief, a mask was applied to define the region of interest (cell stirrer flask).
The video was divided into images based on time, 1 per second. Thresh-
olding was then utilised to define the top of the fluid and used as a marker
to track changes in height from its original position, as a function of time.
Determining the Degree of Curing: was determined using a simple
mass balance. SyMGels (0.5 mL) were centrifuged at 17 000 g for 10 min
to separate the gelled particulate phase from the non-gelled continuous
medium. The mass of supernatant was recovered and weighed. The de-
gree of gelation therefore defined as equal to the mass of the remaining
gelled phase.
Particle volume fraction (𝜑gel) was determined using a similar method
outlined by Garrec et al.[26] (Equation 2):







𝜑gel = 𝜑tot. − 𝜑cont. (3)
where 𝜑 is the volume fraction of the gel (𝜑gel), an equivalent quiescent
gel (𝜑Qgel), and the continuous phase (𝜑cont.). Here, the effects of particle
syneresis “(1 − ϕQgel)” were assumed negligible, providing a mass bal-
ance where the volume occupied by the gel was equal to the total volume
minus the supernatant (Equation 3). Thus, the mass of the supernatant
was converted to volume (density of PBS, 1.065 g cm−3) and subtracted
from the initial sample volume of 0.5 mL.
Particle Size Analysis: Particle size distributions were determined us-
ing static light scattering. A Malvern Mastersizer MS2000 (Malvern Pana-
lytical, UK) equipped with Hydro SM manual small volume sample disper-
sion unit was used to obtain particle size distributions. The technique uses
the Mie theory to calculate particle size, as such, particles were assumed
to be monodisperse homogeneous spheres. Samples were prepared by
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diluting gel particles in distilled water (RI = 1.33) to avoid multiple scat-
tering.
Microscopy: Optical/Fluorescent microscopy was undertaken on an
EVOS M5000 (Invitrogen, UK) microscope for treated/non-treated
SyMGels and cells using phase contrast mode. SyMGels were first diluted
in PBS at a ratio of 1:4 before applying to a standard slide with coverslip.
Fibronectin functionalized particles were imaged using an immunohisto-
chemical technique, whereby particles were treated with a regime of 1%
BSA, primary anti-fibronectin antibody and then secondary goat anti-rabbit
FITC anti-body. Each step was divided by 1 h agitated incubation, followed
by multiple washings/centrifugation (4000 g, 2 min) with PBS.
Confocal laser scanning microscopy (CLSM) was used to determine
particle morphology. Particles were stained with Rhodamine 6G (0.1 mM)
by mixing at room temperature for 20 min. The system was then washed
through repeated mixing with PBS and centrifugation (4000 g for 30 s).
Systems were subsequently diluted at a 1:4 ratio in PBS and placed be-
tween slide and coverslip. An Olympus IX81 (Olympus, UK) confocal mi-
croscope was then used to image the particles using a 543 nm laser and
1 µm spacing (z-stack). Images were compiled using imaging software
(ImageJ).
Rheological Characterization: All rheometry was undertaken using a
Kinexus Ultra+ (Malvern Panalytical, UK) rheometer equipped with 40 mm
serrated parallel plate geometry. All tests were conducted at 20 °C, using
a 2 mm gap height (due to the large particle size). In all cases, samples
were loaded into the rheometer and allowed to equilibrate for 5 min prior
to testing.
Amplitude sweeps were undertaken in stress control mode within the
range of 0.01––100 Pa at a constant frequency of 1 Hz. Frequency depen-
dent data was obtained using a constant stress found within the LVeR for
all samples (0.04 Pa), over a frequency range of 0.01–10 Hz. Data col-
lected at the higher frequency range was affected by geometry inertia and
was, therefore, removed from the data presented.
Viscosity profiles were performed in stress-controlled mode from 0.1 to
100 Pa over a ramp time of 1 min. For lower viscosity samples, tests were
stopped once reaching the second Newtonian plateau to prevent expul-
sion of sample from the gap.
Cell Extraction: All cell work was undertaken on primary ovine chon-
drocytes (unless stated otherwise), which were isolated from ovine articu-
lar knee cartilage (Staffordshire Meat Packers, Stoke-on-Trent, UK). Car-
tilage was removed from the upper condyles of the knee, finely diced,
weighed and rinsed 3 times in a solution of 2% Penicillin Streptomycin
(Gibco) in DPBS (Gibco). The tissue was then agitated using a magnetic
stirrer and incubated overnight at 37 °C, 5% CO2 in chondrocyte isolation
medium consisting of DMEM HAMS F12 (Lonza), supplemented with 2%
Penicillin Streptomycin, ascorbic acid (50 µg mL−1) (Sigma), clostridial
collagenase (1 mg/mL) (Sigma) and deoxyribonuclease (0.1 mg mL−1)
(Sigma). Digested cartilage suspension was filtered through a 100 µm cell
strainer and the supernatant was centrifuged at 600 g for 10 min. The
chondrocytes were seeded at a density of 2 × 104 cells cm−2 in DMEM
(Gibco) supplemented with 10% foetal bovine serum (FBS) (Lonza), 1%
L-Glutamine (Gibco) and 1% Penicillin Streptomycin and expanded for 3–
4 passages.
Cell Culture: Chrondrocytes (2 × 104 cell cm−2) were seeded into
suspension wells (to promote migration in the presence of SyMGels)
24 hrs prior to the application of the SyMGels. Post-treatment systems
were cultured for a further 3 days before testing for metabolic activity
and cell viability. HA-modified SymGels (300 µL) were cultured in hanging
culture (12-well) inserts, with Y201 bone marrow stromal cells (150 µL;
6.66 × 105 cells mL−1) placed atop of the gel suspension. Chondro-
genic medium (DMEM supplemented with L-ascorbic acid 2-phosphate
(50 µg mL−1), dexamethasone (100 nM), TGFß-3 (10 ng mL−1), insulin-
transferrin-selenium, 1% penicillin-streptomycin and 1% L-glutamine)
was added to the well and cells were cultured for 9 days at 37 °C with
21% oxygen. Basic medium (DMEM supplemented with 10% FCS, 1%
penicillin-streptomycin and 1% L-glutamine) and non-HA controls were
included.
Metabolic Activity Assay: was undertaken using a PrestoBlue assay
kit (Invitrogen). In brief, cells were washed once with DPBS, and 1 mL
medium supplemented with 10% PrestoBlue was added to each well. Cells
were then incubated for 4 hrs. 50 µL supernatant from each well was trans-
ferred to one well of a 96 well plate and fluorescence was measured using a
Tecan Spark (Tecan Trading AG, CH) plate reader with excitation/emission
wavelengths set at 550/620 nm.
Live/Dead: was conducted using a ReadyProbes Cell Viability Imaging
Kit (Invitrogen). The assay was conducted in accordance with the manu-
facturer’s instructions by adding two drops of NucBlue live reagent and 2
drops of NucGreen dead reagent directly to each mL culture medium and
incubating for 15 min. Cells were imaged using a fluorescent microscope
equipped with 405 and 488 nm lasers.
Wnt-3A Luciferase Assay: was conducted using Y201 TCF/LEF reporter
cells. Wnt-modified SyMGels (70 µL) were pipetted into a black 96-well
plate. TCF/LEF luciferase reporter cell suspension (20 µL, 1.5 × 106
cells mL−1) was added on top the gels and incubated for 24 hours. Lu-
ciferase expression was determined using the ONE-Step Luciferase As-
say System as per the manufacturer’s instructions. In addition, cells were
seeded into 96-well plate and allowed to adhere overnight, prior to treat-
ment. Wnt-SyMGels (70 µL) were then placed over the cells and incubated
for a further 48 hours. GFP expression was then determined with an EVOS
fluorescent microscope.
Gene Expression: RNA was isolated from cell-seeded SyMGels using
TRI Reagent as per the manufacturer’s instructions and converted into
cDNA using High Capacity cDNA Reverse Transcription Kit, again as per
manufacturer’s instructions. Gene expression analysis was performed us-
ing SYBR Green-based quantitative real-time polymerase chain reaction
(qRT-PCR) with pre-optimised QuantiTect primer assays and an AriaMx
Real-Time PCR System (Agilent Technologies). Relative gene expressions
in the form 2−ΔCT were calculated and expression levels of SOX9 were nor-
malized to expression levels of the housekeeping gene GAPDH1.
Statistical Analysis: All data presented shows the average of at least 3
repeats, with error bars showing the 95% confidence interval. Statistical
significance was probed using one-way and two-way ANOVA and p-value
quoted as * p < 0.05, ** p < 0.01 and *** p < 0.001.
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